2024.05.10
The American Society of Gene & Cell Therapy (ASGCT) hosts the largest conference in the field of cell and gene therapy globally. The 27th annual meeting of ASGCT will take place from May 7-11, 2024, in Baltimore, USA, where leading industry experts from around the world will share the latest advancements in gene and cell therapy.
Cure Genetics is set to showcase several innovative achievements at this year's meeting. These include the CGC729 product developed using Cure Genetics' proprietary AIMS CAR-NKT technology platform. This product, targeting relapsed advanced renal cell carcinoma (RCC), has demonstrated significant efficacy and will be presented for the first time in an oral report featuring its groundbreaking clinical trial data.
Additionally, Cure Genetics will present four research findings related to the development of AAV serotypes. These findings will be displayed in poster format, including a detailed introduction to the VELP™ platform and three new studies supporting the platform's rational design.
Cell Therapy
Addressing the challenges of treating solid tumors, tumor heterogeneity and the suppressive tumor microenvironment are seen as major obstacles for CAR-T cell therapy. Natural Killer T (NKT) cells, a subset of T cells with multifactorial innate immune properties, offer new possibilities for the treatment of solid tumors due to their multifactorial anti-tumor capabilities and ability to modulate the tumor microenvironment.
Cure Genetics' pioneering AIMS CAR-NKT cell therapy platform leverages these properties of NKT cells to enhance tumor infiltration, regulate the tumor environment, and sustain proliferation. This platform has demonstrated good safety and efficacy in the clinical study of its first-in-class pipeline, CGC729, and is being expanded to other autologous/allogeneic product lines.
At the upcoming ASGCT meeting, Cure Genetics will publicly reveal for the first time the breakthrough clinical data of the CGC729 product in patients with relapsed advanced renal cell carcinoma (RCC). CGC729, an autologous CAR-NKT therapy targeting CD70, has shown unique therapeutic potential.
CGC729 ( Anti-CD70 CAR-NKT)
Abstract Title：
Interim Safety and Efficacy Evaluation of Anti-CD70 CAR-NKT (CGC729) Phase I Study for Patients with Relapsed and Refractory Metastatic Renal Cell Carcinoma (R/R mRCC)
Abstract No.：
Late-breaking Abstract No. 10
Format：
口头汇报
Room：
Ballroom 4
Time：
2024/5/10 8:30 am - 8:45 am
Gene Therapy
Adeno-associated virus (AAV) is one of the best vectors for gene therapy. However, its lack of delivery precision can lead to frequent side effects, with the liver and spleen being common off-target organs. Therefore, developing tissue/cell-specific AAV vectors is crucial. Among various AAV vector development platforms, Cure Genetics' proprietary VELP™ platform constructs a high-activity, high-quality, high-throughput AAV virus library using an innovative "progressive" data retrieval method, which maximally retains the richness and precision of information for efficient screening of new tissue/cell-specific AAV vectors. Based on this technology platform, the company is co-developing liver-targeted AAV serotypes with Boehringer Ingelheim and neuron-targeted AAV serotypes with Frametact Limited.
In protein engineering, rational design has always been a powerful complement to directed evolution. Therefore, in the modification of AAV capsids, Cure Genetics employs various rational design methods to fully support the VELP™ platform. For instance, by combining potential N-glycosylation sites on the AAV surface, the relationship between different post-translational modifications and the biological distribution of AAV is studied; and by site-specific modification of antibody fragments on the AAV surface, specific cell-targeting AAV vectors that can effectively infect tumor cells or immune cells are constructed.
At this ASGCT meeting, Cure Genetics will display its four innovative achievements in AAV capsid research through poster presentations, focusing on the development of tissue/cell-targeting AAV serotypes.
01
Abstract Title：
VELPTM: An Efficient AAV Capsid Evolution Platform Based on Novel Viral Library Production Strategy
Abstract No.：
483
Format：
Poster
Room：
Exhibit Hall
Time：
2024/5/8 12:00 pm
02
Abstract Title：
Studies of Biodistribution Regulated by the Combinations of Glycosylation Profile on AAV9
Abstract No.：
484
Format：
Poster
Room：
Exhibit Hall
Time：
2024/5/8 12:00 pm
03
Abstract Title：
The Development of Tumor Targeting AAV
Abstract No.：
1456
Format：
Poster
Room：
Exhibit Hall
Time：
2024/5/10 12:00 pm
04
Abstract Title：
The Development of T Cell Targeting AAV
Abstract No.：
1457
Format：
Poster
Room：
Time:
2024/5/10 12:00 pm
